Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CHDI Foundation and Lundbeck have collaborated for research to investigate a targeted therapy for Huntington's disease (HD), which is a neurodegenerative disease characterized by a triad of behavioral, cognitive, and motor symptoms.
Subscribe to our email newsletter
As part of the partnership, CHDI will conduct pre-clinical studies on a Lundbeck investigative compound to determine the compound’s effect on P2X receptors that may be involved in HD.
Results from the study will influence future research into this and other compounds for HD, said Lundbeck.
CHDI Translational Biology vice president Ignacio Munoz-Sanjuan said one of the company’s important functions is to seek out promising research ideas in the HD field, and this includes this interesting new work on Lundbeck’s compound.
"We hope this research collaboration provides a stepping stone for future therapies that slow the progression of HD," Munoz-Sanjuan added.
Lundbeck president Staffan Schüberg said the company looks forward to working with the group of scientists who share its dedication to the HD community.
"Given our shared commitment, we are thrilled to partner with them and hope that our research will lead to advancements in HD therapeutic options. We are also pleased that this announcement coincides with HD Awareness Month to help draw attention to the need to find therapies for this degenerative neurological disease," Schüberg said.
The collaboration is part of Lundbeck’s continued commitment to its HD Research Initiative, launched in 2010 to identify and ultimately commercialize therapies that may slow or halt the progression of the disease.